Charles River buys WuXi PharmaTech in $1.6 billion deal

Pharmaceutical research company Charles River pays $1.6 billion in cash and stock to acquire Chinese outsourcing company WuXi PharmaTech two-and-a-half years after its listing in the US.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES